Fannin Innovation Studio

What Fannin Innovation Studio does

Fannin Innovation Studio is a Houston-based life-sciences innovation studio founded in 2014 that in-licenses early-stage therapeutic and medical device technologies — primarily from Texas Medical Center institutions such as Baylor College of Medicine, MD Anderson Cancer Center, and the Texas Heart Institute — and advances them through a hybrid model in which the studio acts simultaneously as management team and early-stage investor. Internally, Fannin operates with a core product development team of approximately 20 professionals and supplements this bench through Product Development Associate and Internship programs that have trained more than 300 interns and fellows to date. To date, the studio has brought in more than 35 programs over the past decade, with roughly a dozen currently active and three in the clinic, spanning mechanical circulatory support (Procyrion's Aortix device), inhaled innate-immune therapeutics (Pulmotect's Pul-042), monoclonal antibodies in pediatric oncology (Allterum's 4A10), rapid diagnostics (Brevitest), aptamer platform technology (Raptamer Discovery Group), brain-inflammation therapeutics (Goldenrod), undisclosed indications (Brimstalt), and radiopharmaceuticals (Radiomer, launched 2024).

The studio's revenue and capital mechanics blend non-dilutive grant funding (cumulative ~$75 million from NIH and other federal sources plus state-level grants such as CPRIT), private investor capital deployed across portfolio companies (cumulative ~$185 million), and a no-management-fee co-investment distribution channel called Fannin Direct, which routes accredited investors into spin-out companies through special-purpose vehicles managed by Fannin affiliates, with securities offered through FINRA-member broker-dealer 16 Points LLC. Technologies are de-risked internally and typically spun out into independent NewCo entities during the IND-enabling phase, at which point Fannin brings in outside investors and recruits dedicated management teams (e.g., Eric Fain, former Abbott/St. Jude Medical Group President, installed as President & CEO of Procyrion). The model is designed to address the commercialization gap in non-traditional biotech hubs by combining grant leverage, embedded talent, and institutional investor relationships in markets outside Boston and San Francisco.

Fannin is privately held under Fannin Partners, LLC, domiciled in Texas, and led by Chairman and Founder Leo Linbeck III and Managing Partner Atul Varadhachary, M.D., Ph.D. Recognition includes three SBA Tibbetts Awards (2016, 2017, 2021), FDA Breakthrough Device Designation for Procyrion's Aortix system, Fierce Medtech's Fierce15 designation for Procyrion in 2023, and acceptance into NIDA's Medications Discovery Program in 2022. The studio's forward cadence — roughly one to two spin-outs per year — is supported by an integrated academic deal-sourcing network, a co-investor distribution platform, and a structured internal development pipeline oriented toward IND-enabling milestones rather than revenue-generating product sales.

Name

Fannin Innovation Studio

Legal name

Fannin Partners, LLC

Website

https://fannininnovation.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Fannin Innovation Studio is a Houston-based life-sciences innovation studio that in-licenses early-stage therapeutics and medical devices from Texas Medical Center institutions, de-risks them with a ~20-person internal team, and spins out independent portfolio companies funded by grants and co-investor capital via its Fannin Direct platform.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Studio / Biomedical Asset Development

NAICS

Portfolio Management and Investment Advice (523940), Scientific Research and Development Services (5417)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Studios / Company Builders (FSANAAAH)

Keywords

• Biomedical asset development
• Early-stage life sciences
• Medical device development
• Therapeutic development
• Biotech commercialization

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Co-investment returns: Fannin leads early financing rounds and participates in financing rounds. Returns generated through equity appreciation in portfolio companies spun out from the studio.
2. Fannin Direct platform: Co-investment model with no ongoing management fees. Fannin structures private investment transactions and may offer securities through 16 Points LLC as broker-dealer.
3. Grant funding: NIH and other federal agency grant funding to support early development work. Fannin has received $75 million from grant funding across programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Fannin Innovation Studio is a Houston-based, early-stage life sciences development company that in-licenses therapeutic, diagnostic, and medical device assets from academic institutions, develops them internally through its venture studio model, and spins them out as independent NewCos (portfolio companies). It also operates the Fannin Direct co-investment platform that allows accredited investors to participate in pre-Series A rounds of its portfolio companies on a no-management-fee basis.

Product overview

Fannin Innovation Studio is an early-stage life sciences development group and innovation studio focused exclusively on commercializing biotech and medtech technologies. Rather than a single unified product, Fannin operates a portfolio-based model consisting of multiple Fannin-founded entities (Procyrion, Pulmotect, Brevitest, Allterum, Goldenrod, Brimstalt, Raptamer) advancing therapeutic and medical device programs across various stages of development. The studio also operates Fannin Direct, an investment platform enabling co-investment in portfolio companies, and provides training through Product Development Associate and Internship programs. The pipeline includes approximately a dozen active programs with three in the clinic, developed through a combination of investor funding, government grants, and the studio's ~20-person internal team.

Differentiator

Problem solved

Functional benefit

Products and services

• Fannin Direct Co-Investment Platform

Quantifiable outcome

• $242M+ raised via grant and investor funding
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• GBI BiomanufacturingcoreStrategic or Co-development Partner · 1 January 2024GBI Biomanufacturing and Allterum Therapeutics announced strategic collaboration to manufacture therapeutic antibody for clinical trials
• Baylor College of MedicinecoreStrategic or Co-development PartnerBaylor College of Medicine values its strong relationship with Fannin Innovation Studio. Fannin's internship program provides real-world product development experience addressing the need for more experienced entrepreneurial talent in the Houston biomedical commercialization ecosystem.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerAs the world's leading cancer hospital, MD Anderson generates remarkable breadth of basic sciences and clinical insights. Fannin provides unique approach to partnering with academic researchers to advance innovation with the goal of helping shape the future of patient care.
• Texas Heart InstitutecoreStrategic or Co-development PartnerCollaboration on cardiac device development through Procyrion's Aortix technology
• Texas A&M UniversityminorStrategic or Co-development PartnerAcademic collaboration for technology development
• University of HoustonminorStrategic or Co-development PartnerAcademic collaboration on aptamer technology through Raptamer Discovery Group
• University of Nebraska Medical CenterminorStrategic or Co-development PartnerAcademic collaboration for technology development
• Imperial College LondonminorStrategic or Co-development PartnerAcademic collaboration for technology development
• 16 Points LLCminorChannel Partner/ Reseller/ DistributorFINRA member broker-dealer that may offer certain securities through an agreement with Fannin Direct Holding Company to qualifying investors with pre-existing relationship with Fannin
• Champions OncologyminorStrategic or Co-development PartnerPartnership for oncology studies in myelosuppressed and immunosuppressed patients
• Texas Medical Center (TMC) InnovationcoreStrategic or Co-development PartnerTMC Innovation partner supporting Houston biomedical commercialization ecosystem
• BioHoustoncoreStrategic or Co-development PartnerBioHouston partner supporting life sciences innovation ecosystem

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Regional players

• BioGenerator: BioGenerator is a St. Louis-based biotech startup creator and investor that funds and develops early-stage life-sciences companies out of regional academic research. It employs the same studio-style build-and-spin-out model as Fannin but in a different regional ecosystem.
• Hatteras Venture Partners: Hatteras Venture Partners is a Durham, NC-based early-stage venture firm with deep life-sciences and biotech investment activity emerging from the Research Triangle. It is a regional comparator to Fannin's Houston-based, anchored-in-a-medical-center model.

Direct peers

• Atlas Venture: Atlas Venture is a life-sciences-focused venture firm that builds biotech companies from inception through clinical development, often with an embedded operating team that takes interim leadership roles. Its build-and-spin-out model and emphasis on early-stage therapeutic platforms map closely onto Fannin's approach.
• Celdara Medical: Celdara Medical is an early-stage biotech development company that partners with academic researchers to build, fund, and operate therapeutics companies. It shares with Fannin the model of in-licensing academic IP, providing initial development support, and spinning out independent entities.
• Flagship Pioneering: Flagship Pioneering is a life-sciences-focused venture studio that conceives, builds, and funds biotech companies from invention through clinical development. Like Fannin, it acts as both management team and early investor creating spin-out companies; Flagship is the most analogous model at much greater scale.
• Mission BioCapital: Mission BioCapital is an early-stage life-sciences investor that supports biotech formation around academic research with operating support. Its stage focus and portfolio-development orientation closely resemble Fannin's spin-out-oriented studio model.
• Accelerator Life Science Partners: Accelerator Life Science Partners is an investment and operating platform that supports biotech startups by providing executive leadership, operational infrastructure, and early funding — directly analogous to Fannin's hybrid studio/incubator model in life sciences.

Emerging players

• IndieBio: IndieBio is a biotech-focused accelerator and investor that supports early-stage life-sciences startups with funding, lab space, and operating support. As an accelerator-plus-investor hybrid in biotech, it offers a comparable startup-formation model to Fannin's studio.

Broad incumbents

• ARCH Venture Partners: ARCH Venture Partners is a long-established biotech-focused venture firm that creates and funds early-stage life-sciences companies out of academic research. While much larger and broader in scope, it overlaps with Fannin in sourcing university IP and developing it through dedicated portfolio companies.
• Alexandria Venture Investments: Alexandria Venture Investments is the venture capital arm of Alexandria Real Estate Equities, a large life-sciences-focused REIT and ecosystem investor. While broader and more capital-markets-oriented, it is a comparable institutional participant in early-stage life-sciences company creation and infrastructure.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/FanninStudio
• LinkedInlinkedin.com/company/fannininnovationstudio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fannin Innovation Studio